These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37170593)

  • 21. Prospective study of hallucinations and delusions in Parkinson's disease.
    Holroyd S; Currie L; Wooten GF
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):734-8. PubMed ID: 11385005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
    Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R;
    Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease.
    Giladi N; Treves TA; Paleacu D; Shabtai H; Orlov Y; Kandinov B; Simon ES; Korczyn AD
    J Neural Transm (Vienna); 2000; 107(1):59-71. PubMed ID: 10809404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prevalence of neuropsychiatric disorders in drug-naive subjects with Parkinson's disease (PD)].
    Isais-Millán S; Piña-Fuentes D; Guzmán-Astorga C; Cervantes-Arriaga A; Rodríguez-Violante M
    Gac Med Mex; 2016; 152(3):357-63. PubMed ID: 27335192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.
    Aarsland D; Larsen JP; Cummins JL; Laake K
    Arch Neurol; 1999 May; 56(5):595-601. PubMed ID: 10328255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between age and subtypes of psychotic symptoms in Parkinson's disease.
    Kiziltan G; Ozekmekçi S; Ertan S; Ertan T; Erginöz E
    J Neurol; 2007 Apr; 254(4):448-52. PubMed ID: 17401525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of psychosis in Parkinson's disease: safety considerations.
    Fernandez HH; Trieschmann ME; Friedman JH
    Drug Saf; 2003; 26(9):643-59. PubMed ID: 12814332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel.
    Pahwa R; Isaacson SH; Small GW; Torres-Yaghi Y; Pagan F; Sabbagh M
    Neurol Ther; 2022 Dec; 11(4):1571-1582. PubMed ID: 35906500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
    Panchal SC; Ondo WG
    Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.
    Aarsland D; Larsen JP; Tandberg E; Laake K
    J Am Geriatr Soc; 2000 Aug; 48(8):938-42. PubMed ID: 10968298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease.
    Pacchetti C; Manni R; Zangaglia R; Mancini F; Marchioni E; Tassorelli C; Terzaghi M; Ossola M; Martignoni E; Moglia A; Nappi G
    Mov Disord; 2005 Nov; 20(11):1439-48. PubMed ID: 16028215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychotic symptoms in Parkinson's disease. From description to etiology.
    Papapetropoulos S; Mash DC
    J Neurol; 2005 Jul; 252(7):753-64. PubMed ID: 15999234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropsychiatric Symptoms in Parkinson's Disease.
    Aarsland D; Kramberger MG
    J Parkinsons Dis; 2015; 5(3):659-67. PubMed ID: 26406147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
    Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
    Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease.
    Martinez-Martin P; Leentjens AF; de Pedro-Cuesta J; Chaudhuri KR; Schrag AE; Weintraub D
    Mov Disord; 2016 Mar; 31(3):270-9. PubMed ID: 26695691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the clinical profile of Parkinson's disease between Spanish and Cameroonian cohorts.
    Cubo E; Doumbe J; Martinez-Martin P; Rodriguez-Blazquez C; Kuate C; Mariscal N; Lopez I; Noubissi G; Mapoure YN; Jon JL; Mbahe S; Tchaleu B; Catalan MJ;
    J Neurol Sci; 2014 Jan; 336(1-2):122-6. PubMed ID: 24183853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scales to evaluate psychosis in Parkinson's disease.
    Goetz CG
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S38-41. PubMed ID: 20083004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Neuropsychiatric and cognitive symptoms in Parkinson disease].
    Aarsland D; Pedersen KF; Ehrt U; Bronnick K; Gjerstad MD; Larsen JP
    Tidsskr Nor Laegeforen; 2008 Sep; 128(18):2072-6. PubMed ID: 18846124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease.
    Mueller C; Rajkumar AP; Wan YM; Velayudhan L; Ffytche D; Chaudhuri KR; Aarsland D
    CNS Drugs; 2018 Jul; 32(7):621-635. PubMed ID: 30027401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Range of neuropsychiatric disturbances in patients with Parkinson's disease.
    Aarsland D; Larsen JP; Lim NG; Janvin C; Karlsen K; Tandberg E; Cummings JL
    J Neurol Neurosurg Psychiatry; 1999 Oct; 67(4):492-6. PubMed ID: 10486397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.